While the risk for progression to t-MN is best documented for TP53 mutations [21, 34, 55, 56] both TP53- and PPM1D-driven CH have recently been associated with cardiovascular complications [41, 57, 58]. This evidence concerns the gene PPM1D and therapy-related myeloid neoplasm.